Core Insights - The JPM conference highlighted breakthroughs in ADC, IO dual antibodies, and GLP-1 technologies by Chinese pharmaceutical companies, enabling them to expand globally through licensing and collaborative development [1] - Leading companies have successfully organized their international operations, with some biotech firms achieving breakthroughs in niche areas [1] - The CXO sector is experiencing significant growth, with companies leveraging the CRDMO model and global production capacity, resulting in a continuous increase in orders [1] - By 2026, overseas bases are expected to be densely operational, marking the beginning of a commercialization phase for the industry [1] - Overall, the Chinese pharmaceutical industry is at the starting point of a global value reassessment, with 2026 identified as a critical year for validating transformation outcomes [1]

Core Insights - The international competitiveness of domestic pharmaceutical companies in China is continuously improving, driven by new technologies and supportive national policies for innovative drug development [1][2] - The CXO sector is expected to see significant performance turning points as companies with high overseas business ratios are favored [1] Group 1: Industry Trends - The JPM conference highlighted breakthroughs in technologies such as ADC, IO dual antibodies, and GLP-1, enabling Chinese pharmaceutical companies to expand globally through licensing and collaborative development [1] - Major companies like BeiGene have successfully established international operations, while some biotech firms have achieved breakthroughs in niche areas [1] - The Chinese pharmaceutical industry is at the starting point of a global value reassessment, with 2026 being a critical year for validating transformation outcomes [1] Group 2: Domestic Pharmaceutical Companies - Domestic pharmaceutical companies are accelerating their globalization, characterized by several core trends: 1) Comprehensive iteration of technology platforms such as ADC, multi-antibodies, and small nucleic acids, leading to multiple BIC/FIC potential assets 2) Accelerated internationalization with over $10 billion in transactions with multinational corporations (MNCs) and a continuous rise in innovative drug licensing revenues 3) The year 2026 will see a concentrated period of catalysts for domestic companies, with many initiating global registration studies, key data readouts, and new product applications, showcasing both individual breakthroughs and overall sector acceleration [1] Group 3: CXO Sector Developments - The JPM conference underscored a historic opportunity for the Chinese CXO industry to transition from a "cost advantage" model to a "technology + scale" dual-driven approach [2] - Chinese CXO companies are evolving from "intermediate suppliers" to "global innovation enablers" through their one-stop service platform capabilities in areas like ADC, dual antibodies, and GLP-1 [2] - By 2026, both domestic and international innovations are expected to enter a concentrated catalyst period, with Chinese CXO companies experiencing sustained growth in orders and entering a phase of overseas capacity release [2]

Core Insights - The pharmaceutical and biotechnology industry is experiencing three major trends: deepening internationalization 2.0, unprecedented policy support, and continuous technological breakthroughs [1] Group 1: Internationalization - By 2025, the number of license-out transactions is expected to reach 103, with upfront payments hitting a record high of $8.45 billion, benefiting companies that expand internationally [1] - Companies that successfully venture abroad are enjoying valuation premiums [1] Group 2: Policy Support - There is significant policy support, with improved efficiency in medical insurance negotiations and the establishment of a directory for innovative drugs under commercial insurance for the first time [1] Group 3: Technological Advancements - Continuous breakthroughs in technology are evident, with advancements in ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [1] Group 4: Market Dynamics - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing [1] - Focus is on CDMO companies with strong international capabilities and leading clinical CROs [1] Group 5: Industry Recovery - The upstream supply chain is showing significant recovery, with ample room for increasing domestic production rates [1] - The dual drivers of intelligent, digital production and international expansion are emphasized [1] Group 6: Investment Index - The biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, and medical devices to reflect the overall performance of the biopharmaceutical sector [1] - The index constituents exhibit high growth potential and innovation, focusing on showcasing the comprehensive development level of the biopharmaceutical industry [1]

Core Insights - The CXO sector in A-shares has shown resilience, with 20 out of 29 listed companies reporting year-on-year revenue growth in the first three quarters [1] - The growth in the CXO sector is driven by internationalization and increased demand for innovative drugs, benefiting companies in the upstream of the innovative drug industry chain [1] - The innovative drug sector is experiencing a dual boost from policy support and surging demand, which is stimulating new drug research and development [1] Summary by Categories Industry Trends - Three major trends are emerging in the innovative drug field: 1. Deepening internationalization with an expected 103 license-out transactions and upfront payments reaching $8.45 billion by 2025, leading to valuation premiums for companies going abroad [2] 2. Unprecedented policy support, including improved efficiency in medical insurance negotiations and the establishment of a directory for innovative drugs under commercial insurance for the first time [2] 3. Continuous technological breakthroughs in areas such as ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [2] Market Outlook - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing [2] - There is significant recovery in the upstream industry chain, with ample room for increasing domestic production rates, driven by smart, digital production and international expansion [2] Key Companies - Leading companies in the CXO sector include: - Kelaiying (002821) (06821) - Kanglong Chemical (300759) (03759) - Zhaoyan New Drug (603127) (06127) - WuXi Biologics (02269) - WuXi AppTec (603259) (02359) [3]

Core Viewpoint - The CXO sector in the A-share market is experiencing significant growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters, driven by internationalization and policy support for innovative drug companies [1][2]. Group 1: Industry Trends - Three major trends are emerging in the innovative drug sector: 1. Deepening internationalization 2.0, with an expected 103 license-out transactions and a record upfront payment of $8.45 billion by 2025, leading to valuation premiums for companies going abroad [2]. 2. Unprecedented policy support, including improved efficiency in medical insurance negotiations and the establishment of a commercial insurance directory for innovative drugs [2]. 3. Continuous technological breakthroughs, with advancements in ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [2]. Group 2: Market Outlook - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing, particularly for CDMO companies with strong international capabilities and leading clinical CROs [2]. - The recovery of the upstream industry chain is significant, with ample room for increasing domestic production rates, driven by smart and digital production alongside international expansion [2]. - The capital market's recovery in financing activities and the expansion of innovative drug transactions abroad, combined with a potential recovery in domestic innovative drug R&D demand, are expected to boost CXO companies' performance in the second half of the year [1]. Group 3: Key Companies - Leading companies in the CXO sector include: - Kelaiying (06821) - Kanglong Chemical (03759) - Zhaoyan New Drug (06127) - WuXi Biologics (02269) - WuXi AppTec (02359) [3].

Core Viewpoint - The investment value of innovative drugs is not a short-term pulse but a long-term industrial dividend, with optimal solutions for sharing this dividend through index tools in golden tracks [1] Group 1: Performance of Innovative Drug Indices - Since July, the National Index for Hong Kong Stock Connect Innovative Drugs and the China Securities Innovative Drug Industry Index have reached new highs, with year-to-date increases of 106.7% and 32.3% respectively as of July 31 [2] - The impressive performance of these indices reflects a decade-long transformation of China's innovative drug industry from "follower" to "leader" [2] - Recent inflows into ETFs tracking innovative drug indices have been significant, with a net inflow of 4.26 billion yuan from August 4 to August 8 and over 16 billion yuan since June [2] Group 2: Index Adjustments and Sensitivity - The recent upgrade of the Hong Kong Stock Innovative Drug Index aims to enhance its focus by excluding CXO companies and increasing adjustment frequency from semi-annual to quarterly, effective August 12 [3][4] - This adjustment allows the index to better capture the core drivers of the innovative drug industry, focusing on pharmaceutical companies that lead drug development and hold key patents [3] - The increased adjustment frequency enhances the index's sensitivity, enabling it to quickly identify emerging growth companies in a rapidly evolving market [4] Group 3: Policy Support for Innovative Drugs - The innovative drug industry has received significant policy support this year, with the State Council's 2025 strategic goal to create a globally competitive innovation ecosystem [5] - Multiple regulatory bodies have introduced supportive measures, including optimizing review processes and reopening IPO channels for unprofitable companies [6] - The 2024 medical insurance fund expenditure on innovative drugs is projected to be 3.9 times that of 2020, with an annual growth rate of 40% [7] Group 4: Market Dynamics and Future Outlook - By the end of 2024, China is expected to have 3,575 original innovative drugs in clinical trials, surpassing the U.S. and becoming the global leader [7] - The proportion of first-in-class (FIC) drugs has increased from less than 10% in 2015 to 24% in 2024, indicating a significant enhancement in original innovation capabilities [7] - The innovative drug market in China currently accounts for less than 10% of the total pharmaceutical market, indicating substantial growth potential compared to over 20% in other G20 countries [9] Group 5: Investment Opportunities in Innovative Drugs - The China Securities Innovative Drug Industry Index has shown a year-to-date increase of 32.3%, with significant upside potential remaining [8] - The long-term growth of the innovative drug market is supported by an aging population and increasing demand for treatments for chronic diseases and rare diseases [8] - Investing in ETFs that track the innovative drug sector provides a way to mitigate risks associated with individual stock investments while capitalizing on overall industry growth [9]